Ad
related to: merck & co. news
Search results
Is Merck & Co., Inc. (NYSE:MRK) the Best Dow Stock To Buy According to Hedge Funds?
Insider Monkey via Yahoo Finance· 2 days agoWe recently identified the best dow stocks according to hedge funds. Even though Merck & Co., Inc....
ASCO24: An early look at cancer drug study results
BioPharma Dive via Yahoo Finance· 4 days agoClinical trial abstracts posted Thursday ahead of this year’s ASCO meeting give a peek at anticipated datasets from Immunocore, Merus, J&J and Merck & Co...
McKesson, Merck back Atropos Health’s $33M round to accelerate drug development with AI
VentureBeat· 4 days agoAtropos Health, a healthcare technology company focused on generating personalized real-world...
Why Is Cancer-Focused Merus Stock Trading Over 30% On Friday?
Benzinga via Yahoo Finance· 3 days agoKeytruda (pembrolizumab) is Merck & Co Inc’s (NYSE:MRK) top selling cancer drug. The abstract...
Lilly partners with Aktis, deepening radiopharma investment
BioPharma Dive via Yahoo Finance· 6 days agoAnd in 2023, Merck & Co’s venture arm participated in the company’s Series A extension, which raised...
AstraZeneca’s $80B sales plan leans on cancer drug expansion
BioPharma Dive via Yahoo Finance· 6 days agoBeyond 2030, the drugmaker expects to add radiopharmaceuticals, or hybrid radiation-emitting drugs,...
AltruBio lands up to $225M after shift to immune drug research
BioPharma Dive via Yahoo Finance· 6 days agoThe Phase 2a study AltruBio currently has underway in ulcerative colitis should produce results in...
Boston radiopharmaceuticals startup inks deal worth up to $1.16B with Lilly - Boston Business...
The Business Journals· 6 days agoA Boston radiopharmaceuticals startup that is already backed by three Big Pharma companies now has a...
TME Pharma Announces Convocation of the 2024 Annual General Meeting of Shareholders
Morningstar· 8 hours agoTME Pharma N.V. (Euronext Growth Paris: ALTME) (Paris:ALTME),a biotechnology company focused on developing novel therapies for treatment of cancer by targeting the tumor microenvironment (TME ...
Forbion-backed biotech Progentos debuts with $65M for MS drug
BioPharma Dive via Yahoo Finance· 7 days agoProgentos says the money will go toward expanding its pipeline and pushing an experimental treatment...